Nano-X Imaging to Showcase Nanox.ARC System Live in Europe for the First Time
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy NNOX?
Nano-X Imaging announced that it will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time and present new AI solutions in development at the European Congress of Radiology, ECR, taking place March 4-8, 2026 in Vienna, Austria. "Presenting the Nanox.ARC live in Europe for the first time, a year after receiving CE Mark certification, represents a significant milestone in our European market expansion," said Erez Meltzer, CEO and Acting Chairman of Nanox. "European healthcare systems need advanced imaging solutions that can operate beyond major medical centers, and that is exactly what the Nanox.ARC was designed to do. At ECR 2026, we will highlight new AI capabilities and clinical evidence demonstrating the performance of the capabilities of the Nanox.ARC in lung cancer screening, as shown in clinical studies. We remain focused on making high-quality imaging more affordable, more accessible and available at scale with our end-to-end imaging solutions."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NNOX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NNOX
Wall Street analysts forecast NNOX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.410
Low
7.00
Averages
7.00
High
7.00
Current: 2.410
Low
7.00
Averages
7.00
High
7.00
About NNOX
Nano-X Imaging Ltd is an Israel-based company that develops a digital X-ray source enabling a cost reduction of imaging systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Rise, Market Reacts Positively
- Healthcare Stocks Surge: Late Wednesday afternoon, healthcare stocks rose significantly, driven by the NYSE Health Care Index, indicating a rebound in market confidence towards the sector, possibly reflecting investor optimism regarding future healthcare policies.
- Positive Market Reaction: The rise in healthcare stocks has improved investor sentiment, which may attract more capital into the sector, further driving up stock prices of related companies and enhancing market vitality.
- Optimistic Industry Outlook: The growth potential of the healthcare industry has captured investor attention, particularly in areas of new drug development and medical technology innovation, which are expected to yield substantial revenue growth for related firms.
- Increased Investor Confidence: The uptick in healthcare stocks not only reflects the current positive market sentiment but may also signal signs of future economic recovery, further bolstering investor confidence in long-term investments within the healthcare sector.
See More
Nano-X Imaging Partners with Elite Surgical for Distribution Agreement
- Agreement Signing: Nano-X Imaging has signed a new distribution agreement with Elite Surgical Technologies, allowing the deployment of its FDA-approved digital X-ray system, Nanox.ARC, across Ohio, Indiana, Michigan, Pittsburgh, and West Virginia, marking a significant expansion in the U.S. market.
- Marketing Support: Under the agreement, Elite Surgical will market and support the Nanox.ARC system in orthopedic and post-surgical imaging settings, addressing the need for continuous assessment of bone regeneration and healing processes, which is expected to enhance the product's application in the medical field.
- Deployment Plan: The companies expect to deploy at least five Nanox.ARC systems in the first year of collaboration, increasing to at least ten units in the second year, with adjustments based on market conditions and customer demand, demonstrating confidence in market potential.
- Positive Stock Reaction: Nano-X Imaging's shares rose following the announcement of the partnership, reflecting investor optimism about the company's future growth prospects, particularly in the context of increasing demand for innovation in medical imaging technology.
See More
VisionWave Secures Exclusive Development Rights in Liberia
- Surging Market Demand: RF sensing technologies are becoming increasingly vital in offshore exploration, with the market expected to reach $2 billion, while the broader oil and gas sensor market is projected to hit $14-15 billion over the next decade, indicating robust growth potential.
- Exclusive Development Agreement: VisionWave has signed an exclusive development agreement with the National Oil Company of Liberia, securing rights to develop Blocks LB-4 and LB-5, aiming to advance towards a potential Production Sharing Contract within eight months, marking a significant step in its global expansion strategy.
- Innovative Technology Application: VisionWave plans to integrate its RF sensing and imaging technologies into offshore exploration workflows, aiming to enhance signal detection and resource identification efficiency in complex subsurface environments, thereby upgrading traditional exploration methodologies.
- Strategic Expansion Outlook: This initiative not only reflects VisionWave's strategic positioning in the global energy market but also has the potential to generate significant economic benefits by enhancing exploration capabilities, further solidifying its market position in high-value industries.
See More
Nano-X Imaging Receives FDA Approval for New Functionality
- FDA Approval: Nano-X Imaging's digital X-ray systems, Nanox.ARC and Nanox.ARC X, received FDA clearance for a new cloud-enabled image enhancement feature, positioning them as leading diagnostic solutions in the industry and likely boosting market share.
- Image Enhancement Capability: The new TAP2D feature allows radiologists to generate 2D images directly from tomosynthesis scans, simplifying clinical workflows and enhancing operational efficiency, which is expected to improve customer satisfaction and usage frequency.
- Standalone Imaging Solution: CEO Erez Meltzer noted that this functionality will enable Nanox.ARC to serve as a standalone primary imaging solution, similar to its CE Mark certification in Europe, further expanding its market application scope.
- Commercial Rollout Plans: Nano-X plans to launch the enhancement software as part of its ongoing commercial rollouts of imaging improvements, which is expected to generate new revenue streams and enhance its competitiveness in the medical imaging market.
See More
Nanox Receives FDA Clearance for New Imaging Technology
- FDA Clearance Achieved: Nanox announced that its TAP2D image enhancement capability has received FDA 510(k) clearance, enabling radiologists to generate clear 2D images from digital tomosynthesis scans, enhancing diagnostic efficiency while reducing patient radiation exposure.
- Innovation Driving Efficiency: This new feature not only supports the generation of both 3D and 2D views but also delivers additional views automatically within the existing clinical environment, thereby streamlining workflows and improving the quality of medical services.
- Strategic Market Positioning: This clearance marks a significant advancement in Nanox's strategy to position its tomosynthesis systems as primary diagnostic solutions in the U.S. market, which is expected to further enhance its influence in the global medical imaging sector.
- Ongoing Technology Upgrades: Nanox plans to roll out the TAP2D software to existing installations, demonstrating the company's commitment to continuous technological innovation aimed at improving patient care quality and accessibility to medical services.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
Healthcare Stocks Rise, Market Reacts Positively
- Healthcare Stocks Surge: Late Wednesday afternoon, healthcare stocks rose significantly, driven by the NYSE Health Care Index, indicating a rebound in market confidence towards the sector, possibly reflecting investor optimism regarding future healthcare policies.
- Positive Market Reaction: The rise in healthcare stocks has improved investor sentiment, which may attract more capital into the sector, further driving up stock prices of related companies and enhancing market vitality.
- Optimistic Industry Outlook: The growth potential of the healthcare industry has captured investor attention, particularly in areas of new drug development and medical technology innovation, which are expected to yield substantial revenue growth for related firms.
- Increased Investor Confidence: The uptick in healthcare stocks not only reflects the current positive market sentiment but may also signal signs of future economic recovery, further bolstering investor confidence in long-term investments within the healthcare sector.
See More
Nano-X Imaging Partners with Elite Surgical for Distribution Agreement
- Agreement Signing: Nano-X Imaging has signed a new distribution agreement with Elite Surgical Technologies, allowing the deployment of its FDA-approved digital X-ray system, Nanox.ARC, across Ohio, Indiana, Michigan, Pittsburgh, and West Virginia, marking a significant expansion in the U.S. market.
- Marketing Support: Under the agreement, Elite Surgical will market and support the Nanox.ARC system in orthopedic and post-surgical imaging settings, addressing the need for continuous assessment of bone regeneration and healing processes, which is expected to enhance the product's application in the medical field.
- Deployment Plan: The companies expect to deploy at least five Nanox.ARC systems in the first year of collaboration, increasing to at least ten units in the second year, with adjustments based on market conditions and customer demand, demonstrating confidence in market potential.
- Positive Stock Reaction: Nano-X Imaging's shares rose following the announcement of the partnership, reflecting investor optimism about the company's future growth prospects, particularly in the context of increasing demand for innovation in medical imaging technology.
See More
VisionWave Secures Exclusive Development Rights in Liberia
- Surging Market Demand: RF sensing technologies are becoming increasingly vital in offshore exploration, with the market expected to reach $2 billion, while the broader oil and gas sensor market is projected to hit $14-15 billion over the next decade, indicating robust growth potential.
- Exclusive Development Agreement: VisionWave has signed an exclusive development agreement with the National Oil Company of Liberia, securing rights to develop Blocks LB-4 and LB-5, aiming to advance towards a potential Production Sharing Contract within eight months, marking a significant step in its global expansion strategy.
- Innovative Technology Application: VisionWave plans to integrate its RF sensing and imaging technologies into offshore exploration workflows, aiming to enhance signal detection and resource identification efficiency in complex subsurface environments, thereby upgrading traditional exploration methodologies.
- Strategic Expansion Outlook: This initiative not only reflects VisionWave's strategic positioning in the global energy market but also has the potential to generate significant economic benefits by enhancing exploration capabilities, further solidifying its market position in high-value industries.
See More
Nano-X Imaging Receives FDA Approval for New Functionality
- FDA Approval: Nano-X Imaging's digital X-ray systems, Nanox.ARC and Nanox.ARC X, received FDA clearance for a new cloud-enabled image enhancement feature, positioning them as leading diagnostic solutions in the industry and likely boosting market share.
- Image Enhancement Capability: The new TAP2D feature allows radiologists to generate 2D images directly from tomosynthesis scans, simplifying clinical workflows and enhancing operational efficiency, which is expected to improve customer satisfaction and usage frequency.
- Standalone Imaging Solution: CEO Erez Meltzer noted that this functionality will enable Nanox.ARC to serve as a standalone primary imaging solution, similar to its CE Mark certification in Europe, further expanding its market application scope.
- Commercial Rollout Plans: Nano-X plans to launch the enhancement software as part of its ongoing commercial rollouts of imaging improvements, which is expected to generate new revenue streams and enhance its competitiveness in the medical imaging market.
See More
Nanox Receives FDA Clearance for New Imaging Technology
- FDA Clearance Achieved: Nanox announced that its TAP2D image enhancement capability has received FDA 510(k) clearance, enabling radiologists to generate clear 2D images from digital tomosynthesis scans, enhancing diagnostic efficiency while reducing patient radiation exposure.
- Innovation Driving Efficiency: This new feature not only supports the generation of both 3D and 2D views but also delivers additional views automatically within the existing clinical environment, thereby streamlining workflows and improving the quality of medical services.
- Strategic Market Positioning: This clearance marks a significant advancement in Nanox's strategy to position its tomosynthesis systems as primary diagnostic solutions in the U.S. market, which is expected to further enhance its influence in the global medical imaging sector.
- Ongoing Technology Upgrades: Nanox plans to roll out the TAP2D software to existing installations, demonstrating the company's commitment to continuous technological innovation aimed at improving patient care quality and accessibility to medical services.
See More
Rapid Growth in Cardiac AI Diagnostics Market
- Market Surge: The global medical imaging market reached $45.5 billion in 2026, indicating a significant shift towards AI-native precision, particularly due to the rising demand for heart monitoring in cancer treatments.
- Rise of Cardiac AI Diagnostics: The cardiac AI diagnostics sector hit $2.22 billion in 2026, driven by the urgent need for continuous imaging to monitor heart dysfunction, enhancing the company's competitive edge in the medical technology market.
- Strategic Partnership Enhances Value: Ventripoint's collaboration with Summit Sciences to develop ROI models illustrates how hospitals can achieve cost savings through technological improvements, further solidifying its market position in cardiac care.
- Executive Appointment Fuels Growth: The appointment of David Swetlow as CFO, with extensive experience in medical technology, is expected to accelerate market adoption and revenue growth, driving the execution of the company's commercial strategy.
See More
